EHMT2 and Alzheimer disease: Because AD-activated G9a broadly and simultaneously regulated major signaling pathways that mechanistically contribute to both cognitive and non-cognitive symptoms of AD, MS1262 effects are not ‘one target (G9a) at a time’ but, instead, the drug effect (target) is proteome-wide.